Rockwell Medical to Buy Vantive's Hemodialysis Business for $125M, Targets $400M-$450M Revenue
RMTI sits 41% above its 52-week low of $4.885.
Summary
Rockwell Medical agreed to acquire Vantive's hemodialysis concentrates, AK-98 machines, water treatment systems and related consumables and services, plus a one-million-square-foot manufacturing campus in Medolla, Italy; Vantive's dialyzer portfolio, including the Theranova dialyzer that enables HDx (expanded hemodialysis) therapy, is not included in the transaction. The base price is $125 million, financed entirely by Vantive: two $50 million term loans plus a $25 million convertible note struck at a 100% premium to the 15-day VWAP, with up to $45 million more in contingent consideration tied to revenue and EBITDA milestones. Management estimates the combined business could generate $400 million to $450 million in annual revenue — roughly six times Rockwell's current run rate of about $71 million annualized from Q2's $17.8 million. The company withdrew its 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow to absorb transaction and financing costs. Closing is targeted for mid-2027 and needs regulatory approvals, so nothing hits the P&L before then; the 8:00am EST call today is where management will have to defend the leverage and integration plan.
At the time of this announcement, RMTI was trading at $6.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.9M. The 52-week trading range was $4.89 to $12.90. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: BusinessWire.